Christian Lienhardt

List of Publications by Year
in descending order

99	9,593	47006 47	38395 95
papers	citations	h-index	g-index

102	102	102	10874
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 2016, 63, e147-e195.	5.8	916
2	WHO's new End TB Strategy. Lancet, The, 2015, 385, 1799-1801.	13.7	834
3	Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
4	A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Genetics, 2007, 39, 523-528.	21.4	411
5	A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis. New England Journal of Medicine, 2014, 371, 1588-1598.	27.0	352
6	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nature Genetics, 2010, 42, 739-741.	21.4	332
7	Global tuberculosis drug development pipeline: the need and the reality. Lancet, The, 2010, 375, 2100-2109.	13.7	319
8	World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. European Respiratory Journal, 2017, 49, 1602308.	6.7	302
9	Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet, The, 2012, 379, 1902-1913.	13.7	300
10	Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel. Journal of Infectious Diseases, 2012, 205, S199-S208.	4.0	275
11	Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 2016, 63, 853-867.	5.8	237
12	A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine, 2018, 24, 1708-1715.	30.7	219
13	Global tuberculosis control: lessons learnt and future prospects. Nature Reviews Microbiology, 2012, 10, 407-416.	28.6	199
14	Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. European Journal of Immunology, 2002, 32, 1605.	2.9	191
15	Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2009, 6, e1000146.	8.4	169
16	Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infectious Diseases, The, 2019, 19, e40-e50.	9.1	161
17	Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis. PLoS Medicine, 2009, 6, e1000150.	8.4	159
18	New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future. Journal of Infectious Diseases, 2012, 205, S241-S249.	4.0	159

#	Article	IF	Citations
19	Risk Factors for Tuberculosis Infection in Sub-Saharan Africa. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 448-455.	5.6	139
20	Effectiveness of a Strategy to Improve Adherence to Tuberculosis Treatment in a Resource-Poor Setting. JAMA - Journal of the American Medical Association, 2007, 297, 380.	7.4	134
21	Vitamin D Receptor Polymorphisms and Susceptibility to Tuberculosis in West Africa: A Caseâ€Control and Family Study. Journal of Infectious Diseases, 2004, 190, 1631-1641.	4.0	132
22	CISHand Susceptibility to Infectious Diseases. New England Journal of Medicine, 2010, 362, 2092-2101.	27.0	129
23	Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respiratory Medicine,the, 2015, 3, 201-209.	10.7	116
24	Polymorphism within the Interferon-Î³/Receptor Complex Is Associated with Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 339-343.	5.6	111
25	New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	2.6	106
26	Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0199121.	3.2	103
27	Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10364-10368.	7.1	102
28	CD209 Genetic Polymorphism and Tuberculosis Disease. PLoS ONE, 2008, 3, e1388.	2.5	100
29	Evaluation of Tuberculosis Diagnostics in Children: 2. Methodological Issues for Conducting and Reporting Research Evaluations of Tuberculosis Diagnostics for Intrathoracic Tuberculosis in Children. Consensus From an Expert Panela. Journal of Infectious Diseases, 2012, 205, S209-S215.	4.0	99
30	Tuberculosis Contacts but Not Patients Have Higher Gamma Interferon Responses to ESAT-6 than Do Community Controls in The Gambia. Infection and Immunity, 2001, 69, 6554-6557.	2.2	93
31	Risk Factors for Tuberculosis Infection in Children in Contact With Infectious Tuberculosis Cases in The Gambia, West Africa. Pediatrics, 2003, 111, e608-e614.	2.1	93
32	Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared With Separate Drugs for Treatment of Pulmonary Tuberculosis. JAMA - Journal of the American Medical Association, 2011, 305, 1415.	7.4	88
33	Mapping of a Novel Susceptibility Locus Suggests a Role for MC3R and CTSZ in Human Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 203-207.	5.6	83
34	A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2012, 56, 2091-2098.	3.2	77
35	Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infectious Diseases, The, 2012, 12, 415-421.	9.1	74
36	Risk factors for pulmonary tuberculosis: a clinic-based case control study in The Gambia. BMC Public Health, 2006, 6, 156.	2.9	71

#	Article	IF	Citations
37	Sensitivity of IFN-Î³ Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS Progression. PLoS ONE, 2008, 3, e1441.	2.5	69
38	Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 936-943.	4.3	68
39	Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm?. Tropical Medicine and International Health, 2004, 9, 833-841.	2.3	64
40	A bibliometric analysis of tuberculosis research, 2007â€“2016. PLoS ONE, 2018, 13, e0199706.	2.5	64
41	Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infectious Diseases, The, 2013, 13, 449-458.	9.1	59
42	Polarization of PPD-Specific T-Cell Response of Patients with Tuberculosis from Th0 to Th1 Profile after Successful Antimycobacterial Therapy orIn VitroConditioning with Interferon- Î± or Interleukin-12. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 187-194.	2.9	58
43	Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis. Journal of Infectious Diseases, 2012, 205, S250-S257.	4.0	58
44	Priorities for tuberculosis research: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 886-892.	9.1	56
45	Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infectious Diseases, The, 2006, 6, 522-528.	9.1	55
46	Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study. The Lancet Global Health, 2019, 7, e219-e226.	6.3	51
47	Evaluation of the Prognostic Value of IFN-Î³ Release Assay and Tuberculin Skin Test in Household Contacts of Infectious Tuberculosis Cases in Senegal. PLoS ONE, 2010, 5, e10508.	2.5	51
48	Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions. PLoS Medicine, 2016, 13, e1001965.	8.4	50
49	Advancing the development of tuberculosis therapy. Nature Reviews Drug Discovery, 2012, 11, 171-172.	46.4	49
50	Immune Responses to Mycobacterial Antigens in the Gambian Population: Implications for Vaccines and Immunodiagnostic Test Design. Infection and Immunity, 2004, 72, 381-388.	2.2	47
51	Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. PLoS ONE, 2008, 3, e2921.	2.5	45
52	Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam. PLoS ONE, 2014, 9, e84866.	2.5	38
53	Bactericidal Activity of a Single-Dose Combination of Ofloxacin plus Minocycline, with or without Rifampin, against Mycobacterium leprae in Mice and in Lepromatous Patients. Antimicrobial Agents and Chemotherapy, 1998, 42, 1115-1120.	3.2	36
54	Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review. PLoS Medicine, 2012, 9, e1001358.	8.4	35

#	Article	IF	Citations
55	Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacology & Toxicology, 2014, 15, 61.	2.4	34
56	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	1.9	33
57	Risk Factors for Positive Tuberculin Skin Test in Guinea-Bissau. Epidemiology, 2007, 18, 340-347.	2.7	32
58	Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 594-601.	1.8	32
59	Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. European Respiratory Journal, 2014, 44, 1412-1417.	6.7	32
60	Interleukinâ€8 Polymorphism Is Not Associated with Pulmonary Tuberculosis in The Gambia. Journal of Infectious Diseases, 2004, 189, 1545-1546.	4.0	31
61	Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy. Journal of Infectious Diseases, 2012, 205, S159-S168.	4.0	30
62	A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials, 2012, 13, 61.	1.6	28
63	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
64	From latent to patent: rethinking prediction of tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 243-244.	10.7	26
65	Target regimen profiles for treatment of tuberculosis: a WHO document. European Respiratory Journal, 2017, 49, 1602352.	6.7	25
66	Research Questions and Priorities for Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses. PLoS ONE, 2012, 7, e42479.	2.5	24
67	Tuberculosis in Brazil and cash transfer programs: A longitudinal database study of the effect of cash transfer on cure rates. PLoS ONE, 2019, 14, e0212617.	2.5	23
68	What Research Is Needed to Stop TB? Introducing the TB Research Movement. PLoS Medicine, 2011, 8, e1001135.	8.4	22
69	Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS ONE, 2016, 11, e0155968.	2.5	22
70	Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development. Clinics in Chest Medicine, 2009, 30, 755-768.	2.1	21
71	Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Medicine, 2019, 16, e1002767.	8.4	20
72	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Medicine, 2017, 14, e1002202.	8.4	20

#	Article	IF	Citations
73	Advances in clinical trial design for development of new TB treatments: A call for innovation. PLoS Medicine, 2019, 16, e1002769.	8.4	19
74	Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries. PLoS Medicine, 2007, 4, e302.	8.4	19
75	Variants of the CD40 ligand gene are not associated with increased susceptibility to tuberculosis in West Africa. Immunogenetics, 2003, 55, 502-507.	2.4	16
76	Advances in clinical trial design: Weaving tomorrowâ€™s TB treatments. PLoS Medicine, 2020, 17, e1003059.	8.4	16
77	Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo Simulations. Antimicrobial Agents and Chemotherapy, 2013, 57, 4164-4171.	3.2	14
78	First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea. Infection, Genetics and Evolution, 2015, 33, 314-319.	2.3	14
79	Tuberculosis Drug Development. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1107-1113.	5.6	13
80	Tuberculosis research and development: seeding the future. Lancet Respiratory Medicine,the, 2018, 6, 242-244.	10.7	13
81	Introducing risk inequality metrics in tuberculosis policy development. Nature Communications, 2019, 10, 2480.	12.8	13
82	Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance. PLoS Medicine, 2019, 16, e1002915.	8.4	12
83	Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
84	BCG: the story continues. Lancet, The, 2005, 366, 1414-1416.	13.7	10
85	Improving tuberculosis control: an interdisciplinary approach. Lancet, The, 2006, 367, 949-950.	13.7	9
86	Fundamental research is the key to eliminating TB. Nature, 2014, 507, 401-401.	27.8	9
87	Harnessing the Power of Data to Guide Local Action and End Tuberculosis. Journal of Infectious Diseases, 2017, 216, S669-S672.	4.0	7
88	The blueprint for vaccine research & development: Walking the path for better TB vaccines. Tuberculosis, 2012, 92, S33-S35.	1.9	6
89	TB Elimination Requires Discovery and Development of Transformational Agents. Applied Sciences (Switzerland), 2020, 10, 2605.	2.5	6
90	Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Medicine, 2022, 19, e1004032.	8.4	6

#	Article	IF	Citations
91	Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research. Clinical Infectious Diseases, 2016, 63, 370-375.	5.8	5
92	Would pan-tuberculosis treatment regimens be cost-effective?. Lancet Respiratory Medicine,the, 2018, 6, 486-488.	10.7	5
93	Estimating the yield of tuberculosis from key populations to inform targeted interventions in South Africa: a scoping review. BMJ Global Health, 2020, 5, e002355.	4.7	4
94	French research strategy to tackle antimicrobial resistance. Lancet, The, 2020, 395, 1239-1241.	13.7	3
95	Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis. BMC Medicine, 2022, 20, 182.	5.5	2
96	Priorities for global political momentum to end TB: a critical point in time. BMJ Global Health, 2018, 3, e000830.	4.7	0
97	Priority Areas for Research on Anti-Tuberculosis Treatment. , 2021, , 423-428.		0
98	An Overview of Research Priorities in Tuberculosis. , 2021, , 385-393.		0
99	3. La tuberculose dans le monde aujourd'huiÂ: enjeux, recherche et perspectives. , 2011, , 59-74.		0